Biomedical Innovation Has Science Overtaken the System?

Size: px
Start display at page:

Download "Biomedical Innovation Has Science Overtaken the System?"

Transcription

1 Adaptive Pathways for Transformative Medicinal Products. A New Paradigm with the Enhanced Application of Real-World Evidence? ISPOR 20 th Annual European Congress, Glasgow, Scotland Issue Panel 21, Wednesday, 8 th November 2017, 10:00-11:00 Biomedical Innovation Has Science Overtaken the System? Empowered patients Precision Medicine Need for Speed Adaptive Trials Adaptive Pathways (PRIME/CMA) Outcome and Value Uncertainties 1

2 The Panel Three Diverse Perspectives The Patients Voice Nicola Bedlington Secretary General, European Patients Forum and Co- Founder, The Patient Access Partnership PACT, Brussels, Belgium Health Technology Assessment Perspectives Ad Schuurman MA, Senior Medical Officer, EMA, London, UK, Head of the International Department, National Health Care Institute (ZIN), The Netherlands The Biopharma Viewpoint Rob Thwaites MA, MCom, Senior Director, Takeda, London, UK Nicola Bedlington The Patients Voice Adaptive Pathways (MAPPs) to foster access to beneficial treatment for the right patient groups at the earliest appropriate time in the product life span in a sustainable fashion (Adapt Smart) Opportunity to address bottlenecks evident in standard pathways 2

3 The Patients Voice Focus on : high unmet medical need Attention to : safety profile of products and patients trade-off preferences Attention to : capacity to collect of quality and useful data reducing uncertainties Key: Involvement all relevant stakeholders engaging early dialogue The Patients Voice Trade-off benefit/risk is key to patients Not static or linear. Expectations and perceptions of benefits and risks change over time (of illness) and according to age, role in society, culture. Analysis of benefits and risks may result in highly diverse perspectives 3

4 Priorities Communication/Information Education of patients enrolled in the process Key role of patient organisations as coaches and information providers Clear legal framework to address issues such as disinvestment Consideration of ethical aspects Early involvement of all stakeholders Ad Schuurman Payers Want Control on volume (indication, start-stop, dose) Control on data (real life, transparent) Agreement registry, definitions data, when assessed, consequences assessments, NL and EMA experience: dynamics line therapy, near/off label, changing start/stop, doses, combination therapy, transaction costs Prevent decline in quality of evidence 4

5 Payers Want Control on costs (adaptive reimbursement, mutual acceptable prices) Initial prices, future price (per country?), how to be paid (confidential?) Restrict MAPPs to special cases Patients who cannot wait clinical development & benefit/risk evaluation: deteriorate irreversibly or die. Or urgent public health protection. Major improvement expected. Realistic exit strategy Agreement, patients/doctors aware Iterative development: Approval in stages Confirming benefit/risk balance of a product Gathering more evidence through time Early dialogue with multiple stakeholders The use of real world evidence to supplement clinical trial data Rob Thwaites Adaptive Pathways 5

6 GetReal and Evidence of Effectiveness Aim To develop a common understanding amongst health care decision makers and pharma R&D of the acceptability and usefulness of innovative development programmes which use RWE to estimate the effectiveness of new medicines HTAs Other stakeholders Regulators Alternative Evidence Development Pharma R&D Patients Clinicians GetReal: How can Pharma Take on Board? Enhance evidence plans and clinical development plans with learnings from GetReal Introduce a systematic approach for effectiveness planning Incorporate into project teams activities Support new ideas with internal and external expertise Engage earlier in scientific advice processes 6

7 Panel Debate The Role of the Patient Community Are patients willing to accept greater risks in return for early access to novel drugs? Which challenges to the equitable and timely access of transformative medicines remain across Europe? What is the patients role in HTA and P&R decisionmaking and how can this enhance timely access? Panel Debate Ensuring Value in Greater Uncertainty How do HTA bodies and payers deal with the challenges of fewer data & increased uncertainty? How can the stakeholders collaborate with HTA to achieve timely access to innovative treatments? What is the state of play for value-based MEAs in Europe and what are potential ways forward? 7

8 Panel Debate Advancing Evidence Generation with RWE RCTs and RWE polar opposites or complimentary? Can we accept some bias to get closer to the truth? Can regulatory and HTA requirements be aligned in early parallel EMA/HTA scientific consultations? Which areas of RWE require further development to enhance early access HTA/P&R decision-making? Questions & Answers Contributions from the Audience Please use the microphones State your name and affiliation Name the panellist(s) that you are addressing Thank you for your contributions to the debate 8

9 Thank You for Your Participation Slides and Debate Minutes will be available via ISPOR and LinkedIn Acknowledgements: Glasgow images by Shutterstock, icons by Freepic.com 9

Andalusian Agency for Health Technology Assessment (AETSA)

Andalusian Agency for Health Technology Assessment (AETSA) Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction

More information

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? Department director Øyvind Melien Reviews and HTA, Norwegian

More information

December Eucomed HTA Position Paper UK support from ABHI

December Eucomed HTA Position Paper UK support from ABHI December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing

More information

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process

More information

Integrated Scientific Advice Workshop: ISPOR Glasgow

Integrated Scientific Advice Workshop: ISPOR Glasgow Integrated Scientific Advice Workshop: ISPOR Glasgow Early Integrated Scientific Advice in Product Development: Get Real and Adapt to Accelerate Patient Access ICONplc.com Overview At today s patient-centered

More information

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as: HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually

More information

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint 'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented

More information

EU Cooperation on Health Technology Assessment

EU Cooperation on Health Technology Assessment Strategy for EU Cooperation on Health Technology Assessment Strategy for EU cooperation on Health Technology Assessment (HTA) The HTA Network is a voluntary network, set up by Directive2011/24 (article

More information

Changing landscape - changing paradigms

Changing landscape - changing paradigms IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute

More information

EUROPE March Brussels, Belgium CALL FOR ABSTRACTS. Join Us at the Crossroads of Healthcare. DIAglobal.org/Europe2020 #DIAEurope2020

EUROPE March Brussels, Belgium CALL FOR ABSTRACTS. Join Us at the Crossroads of Healthcare. DIAglobal.org/Europe2020 #DIAEurope2020 EUROPE 2020 17-19 March Brussels, Belgium CALL FOR ABSTRACTS Join Us at the Crossroads of Healthcare I1 Steering Committee Francis Arickx INAMI, Belgium Matthieu Boudes EPF, Belgium Sini Eskola EFPIA,

More information

IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?

IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute

More information

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark EUnetHTA European network for Health Technology Assessment DATABASES, REGISTRIES AND OTHER DATA CAPTURE TOOLS: HOW CAN WE AVOID MULTIPLICITY AND CREATE AN INTEGRATED DATA-CAPTURE APPROACH ALONG THE PRODUCT

More information

How can value be measured and assessed?

How can value be measured and assessed? Dávid Dankó, PhD, MSc Corvinus University of Budapest Institute of Management david.danko at uni-corvinus.hu How can value be measured and assessed? ISPOR 5 th Asia-Pacific Conference, Taipei, 2 September

More information

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on

More information

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI SAMED, Annual Conference, May 29 th 2014 From «Does

More information

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) BACKGROUND (Reason or Purpose) The purpose of this Policy is to provide clear principles and guidance about

More information

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,

More information

National Coordinated Registry Network (CRN) Think-tank

National Coordinated Registry Network (CRN) Think-tank National Coordinated Registry Network (CRN) Think-tank The Value of Real World Data for Innovation within FDA What can CRNs offer? Murray Sheldon, MD Associate Director for Technology and Innovation FDA/CDRH

More information

Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases

Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases In 2017 the multi-stakeholder initiative was set up to: Facilitate a shared understanding of the

More information

EU s Innovative Medical Technology and EMA s Measures

EU s Innovative Medical Technology and EMA s Measures EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency

More information

Final Minutes of EMA/EUnetHTA meeting

Final Minutes of EMA/EUnetHTA meeting 4 June 2013 EMA/297283/2013 14 May 2013 chaired by Hans-Georg Eichler and Finn Børlum Kristensen Role Chairs Participants Name Hans-Georg Eichler and Finn Børlum Kristensen EMA: Peter Arlett, Michael Berntgen,

More information

ABHI Response to the Kennedy short study on Valuing Innovation

ABHI Response to the Kennedy short study on Valuing Innovation ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.

More information

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and

More information

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry

More information

TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY

TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY A/Prof Tracy Merlin Adelaide Health Technology Assessment (AHTA) School of Population Health

More information

Before I talk through the strategy itself, I want to tell you more about why

Before I talk through the strategy itself, I want to tell you more about why This presentation was given by Dr Annette Bramley, the Healthcare Technologies Theme leader. She thanked Professor Nelson and Professor Taylor for their presentations, and thanked everyone at the meeting

More information

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 Zoe Garrett, Senior Technical Adviser Lead WP7 National Implementation and Impact National Institute for Health and Care Excellence

More information

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... Table Of Content... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D08 - HAI Europe Newsletter (EN)... 7 D01 - HAI Europe leaflet (EN)... 7 D02 - Briefing Papers and statements

More information

Life Sciences Regulatory

Life Sciences Regulatory Life Sciences Regulatory Pharmaceuticals 2018 2 Life Sciences Regulatory Pharmaceuticals 2018 Top ranked in Chambers and Legal 500 for Life Sciences, pharmaceuticals and biotechnology. Allen & Overy LLP

More information

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

25 th Workshop of the EURORDIS Round Table of Companies (ERTC) 25 th Workshop of the EURORDIS Round Table of Companies (ERTC) Healthcare Companies & European Reference Networks: Expectations & Potential for Collaboration Introduction Tuesday 26 September, 2017 (09:00

More information

SHTG primary submission process

SHTG primary submission process Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG 14-16 Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments

More information

Higher Education Contribution to Health Science Innovation

Higher Education Contribution to Health Science Innovation Scottish University of the Year 2017 Higher Education Contribution to Health Science Innovation Professor Sir Pete Downes Principal, University of Dundee Lead Member for Health, Universities Scotland 28

More information

HealthTech: What does it mean for compliance?

HealthTech: What does it mean for compliance? HealthTech: What does it mean for compliance? May 2018 Agenda 11:15 AM 11:30 AM Introduction Kathleen Meriwether, Americas Leader - Life Sciences Fraud Investigation & Dispute Services, EY 11:30 AM 12:15

More information

Translational scientist competency profile

Translational scientist competency profile C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective

More information

IMI s ADAPT SMART Draws to a Close, Outlines Path Forward for Continuing Early Stakeholder Engagement

IMI s ADAPT SMART Draws to a Close, Outlines Path Forward for Continuing Early Stakeholder Engagement MEETING REPORT IMI s ADAPT SMART Draws to a Close, Outlines Path Forward for Continuing Early Stakeholder Engagement March 23, 2018 Budapest: On March 21 st and 22 nd, ADAPT SMART held its closing meeting

More information

Knowledge Translation: Where Are We? and Where Do We Go From Here?

Knowledge Translation: Where Are We? and Where Do We Go From Here? Knowledge Translation: Where Are We? and Where Do We Go From Here? Ian D Graham, PhD, FCAHS PRAM- McGill University February 13, 2013 The Problem Knowledge Translation The Solution BUT What do we really

More information

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki The EFPIA Perspective on the GDPR Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference 26-27.9.2017, Helsinki 1 Key Benefits of Health Data Improved decision-making Patient self-management CPD

More information

Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective

Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective Hong Li, PhD., MPH Group Director, Bristol-Myers Squibb Adjunct Associate Professor University of Cincinnati, USA; and DUKE-NUS

More information

Security and Risk Assessment in GDPR: from policy to implementation

Security and Risk Assessment in GDPR: from policy to implementation Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is

More information

NHS SOUTH NORFOLK CLINICAL COMMISSIONING GROUP COMMUNICATIONS AND ENGAGEMENT STRATEGY

NHS SOUTH NORFOLK CLINICAL COMMISSIONING GROUP COMMUNICATIONS AND ENGAGEMENT STRATEGY NHS SOUTH NORFOLK CLINICAL COMMISSIONING GROUP COMMUNICATIONS AND ENGAGEMENT STRATEGY 2014-16 Ref Number: Version 3.0 Status FINAL DRAFT Author Oliver Cruickshank Approval body Governing Body Date Approved

More information

Medical Education Activities

Medical Education Activities Medical Education Activities Author: Marie-Claire PICKAERT EFPIA Deputy Director General BioMed Alliance Brussels, 9 November 2016 MCP 07-11--2016 Declaration of Interest Marie-Claire Pickaert is a full-time

More information

Ethical issues raised by big data and real world evidence projects. Dr Andrew Turner

Ethical issues raised by big data and real world evidence projects. Dr Andrew Turner Ethical issues raised by big data and real world evidence projects Dr Andrew Turner andrew.turner@oii.ox.ac.uk December 8, 2017 What is real world evidence and big data? Real world evidence is evidence

More information

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization Accenture Research Note: Key findings

More information

Implementation of Systems Medicine across Europe

Implementation of Systems Medicine across Europe THE CASyM ROADMAP Implementation of Systems Medicine across Europe A short roadmap guide 0 The road toward Systems Medicine A new paradigm for medical research and practice There has been a data generation

More information

The Assessment of Benefits and Harms and Their Relative Importance for Patients, Industry and Agencies: How should they be captured?

The Assessment of Benefits and Harms and Their Relative Importance for Patients, Industry and Agencies: How should they be captured? The Assessment of Benefits and Harms and Their Relative Importance for Patients, Industry and Agencies: How should they be captured? 2-3 April 2014 PROGRAMME Woodlands Park Hotel, Cobham, Surrey, UK CENTRE

More information

EU Research Integrity Initiative

EU Research Integrity Initiative EU Research Integrity Initiative PROMOTING RESEARCH INTEGRITY IS A WIN-WIN POLICY Adherence to the highest level of integrity is in the interest of all the key actors of the research and innovation system:

More information

Exploring Canada s early scientific advice: Global and Canadian context, CADTH and Health Canada perspectives. October 18, 2017

Exploring Canada s early scientific advice: Global and Canadian context, CADTH and Health Canada perspectives. October 18, 2017 Exploring Canada s early scientific advice: Global and Canadian context, CADTH and Health Canada perspectives October 18, 2017 1 Today s par+cipants Panelist Panelist Panelist Panelist Don Husereau Health

More information

POWERED BY SCRIP SPONSORED BY

POWERED BY SCRIP SPONSORED BY GETTING IT RIGHT Drawing Together Key Stakeholders To Shape The Real-World Data Revolution POWERED BY SCRIP SPONSORED BY 1 February 2019 During an expert panel convened by PAREXEL and Pharma Intelligence

More information

Priorities for medical research in the UK

Priorities for medical research in the UK Priorities for medical research in the UK Sir Leszek Borysiewicz Medical Research Council The Foundation for Science and Technology, 20 May 2009 MRC mission Encourage and support high-quality research

More information

Project: HELIUM - Health Innovation Experimental Landscape through Policy Improvement -

Project: HELIUM - Health Innovation Experimental Landscape through Policy Improvement - European Union European Regional Development Fund Sharing solutions for better regional policies Annex 1 Action plan template Produced by each region, the action plan is a document providing details on

More information

Webinar IMI2 - Call 15 Digital endpoints in neurodegenerative and immunemediated

Webinar IMI2 - Call 15 Digital endpoints in neurodegenerative and immunemediated Webinar IMI2 - Call 15 Digital endpoints in neurodegenerative and immunemediated diseases 18.07.2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction Colm Carroll, IMI The Call topic Vaibhav

More information

Roche Pharma Report Relating to EUnetHTA HTA Core Model Applications for Pharmaceuticals. December 21 st 2014

Roche Pharma Report Relating to EUnetHTA HTA Core Model Applications for Pharmaceuticals. December 21 st 2014 Roche Pharma Report Relating to EUnetHTA HTA Core Model Applications for Pharmaceuticals December 21 st 2014 Table of Contents 1 Introduction... 3 2 The HTA Core Model... 4 3 Method of Research... 5 4

More information

Mapping of HTA in Europe " Regulatory and Reimbursement Atlas"

Mapping of HTA in Europe  Regulatory and Reimbursement Atlas CIRS- Centre for Innovation in Regulatory Science 1 CONSENSUS TRUST ACCESS Mapping of HTA in Europe " Regulatory and Reimbursement Atlas" Tina Wang Manager, HTA Programme twang@cirsci.org 20 May 2016 Brussels,

More information

Innovating to survive, collaborating to thrive 2017 Pharmaceutical R&D leader survey

Innovating to survive, collaborating to thrive 2017 Pharmaceutical R&D leader survey Innovating to survive, collaborating to thrive 2017 Pharmaceutical R&D leader survey Contents Foreword 01 Analysis of survey findings 02 Drivers influencing R&D priorities 02 Strong headwinds affecting

More information

Health & Social Care Industrial Innovation

Health & Social Care Industrial Innovation Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging

More information

EMA-HTA workshop Bringing together stakeholders for early dialogue in medicines development

EMA-HTA workshop Bringing together stakeholders for early dialogue in medicines development EMA-HTA workshop Bringing together stakeholders for early dialogue in medicines development Report from the public workshop hosted by the European Medicines Agency (EMA) in London on 26 November 2013 An

More information

EMA experience with the review of digital technology proposals in medicine development programmes

EMA experience with the review of digital technology proposals in medicine development programmes EMA experience with the review of digital technology proposals in medicine development programmes 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Francesca Cerreta, Scientific Advice An agency

More information

ECU Research Commercialisation

ECU Research Commercialisation The Framework This framework describes the principles, elements and organisational characteristics that define the commercialisation function and its place and priority within ECU. Firstly, care has been

More information

Smart devices. How to unlock their potential in the real world. Tobias Handschuh, Ernst & Young

Smart devices. How to unlock their potential in the real world. Tobias Handschuh, Ernst & Young Smart devices How to unlock their potential in the real world Tobias Handschuh, Ernst & Young Smart devices How to unlock their potential in the real world Smart injectors situation today Expectations

More information

Compliance for Eucomed: The Medical Technology Industry s s Perspective

Compliance for Eucomed: The Medical Technology Industry s s Perspective Compliance for Eucomed: The Medical Technology Industry s s Perspective Rome, May 29, 2009 John Wilkinson Chief Executive - Eucomed Outline Overview of the Medical Technology Industry What is it? How big

More information

Technology and Innovation in the NHS Scottish Health Innovations Ltd

Technology and Innovation in the NHS Scottish Health Innovations Ltd Technology and Innovation in the NHS Scottish Health Innovations Ltd Introduction Scottish Health Innovations Ltd (SHIL) has, since 2002, worked in partnership with NHS Scotland to identify, protect, develop

More information

IoT in Health and Social Care

IoT in Health and Social Care IoT in Health and Social Care Preserving Privacy: Good Practice Brief NOVEMBER 2017 Produced by Contents Introduction... 3 The DASH Project... 4 Why the Need for Guidelines?... 5 The Guidelines... 6 DASH

More information

Roadmap for European Universities in Energy December 2016

Roadmap for European Universities in Energy December 2016 Roadmap for European Universities in Energy December 2016 1 Project partners This project has received funding from the European Union s Seventh Framework Programme for research, technological development

More information

Cultural Evolution Is the future in our own hands?

Cultural Evolution Is the future in our own hands? Cultural Evolution Is the future in our own hands? Dr Paul Litchfield - Chief Medical Officer, BT Group Laura Collins - Carer and East Belfast ICP member Colette Goldrick - NI Director, APBI Dr Anne Kilgallen

More information

Heads of European Radiological

Heads of European Radiological Heads of European Radiological protection Competent Authorities Association O. Guzmán French Nuclear Safety Authority, ASN HERCA Secretariat Summary - Background - Terms of Reference (ToR): - Objectives

More information

Our position. ICDPPC declaration on ethics and data protection in artificial intelligence

Our position. ICDPPC declaration on ethics and data protection in artificial intelligence ICDPPC declaration on ethics and data protection in artificial intelligence AmCham EU speaks for American companies committed to Europe on trade, investment and competitiveness issues. It aims to ensure

More information

Enpr EMA. Enpr-EMA. European Network of Paediatric Research at the European Medicines Agency

Enpr EMA. Enpr-EMA. European Network of Paediatric Research at the European Medicines Agency Enpr EMA European Network of Paediatric Research at the European Medicines Agency Enpr-EMA European Network of Paediatric Research at the European Medicines Agency An agency of the European Union Enpr

More information

FDA Centers of Excellence in Regulatory and Information Sciences

FDA Centers of Excellence in Regulatory and Information Sciences FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in

More information

[Definitions of terms that are underlined are found at the end of this document.]

[Definitions of terms that are underlined are found at the end of this document.] Policy Direction - Pharmaceutical Industry Relationships [Definitions of terms that are underlined are found at the end of this document.] Rationale and Relationship to Mission, Principles and Values The

More information

Annual Benefit-Risk Workshop

Annual Benefit-Risk Workshop Annual Benefit-Risk Workshop Implementing an Internationally Acceptable Framework for the Benefit- Risk Assessment of Medicines: How close are we to this objective? 20-21 June 2013 PROGRAMME Venue: The

More information

European Connected Health Alliance Bringing needs and solutions together for the Future of Health. ECHAlliance Update

European Connected Health Alliance Bringing needs and solutions together for the Future of Health. ECHAlliance Update European Connected Health Alliance Bringing needs and solutions together for the Future of Health ECHAlliance Update Gregor Cuzak, International Ecosystem Coordinator - Gregor@echalliance.com Damian O

More information

ENCePP Work Plan

ENCePP Work Plan EMA/150117/2014 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP

More information

Twenty-Thirty Health care Scenarios - exploring potential changes in health care in England over the next 20 years

Twenty-Thirty Health care Scenarios - exploring potential changes in health care in England over the next 20 years Twenty-Thirty Health care Scenarios - exploring potential changes in health care in England over the next 20 years Chris Evennett & Professor James Barlow The context Demographics On-going financial constraints

More information

6 & 7 December. current concepts for. Smart health in orthopaedics. congress.

6 & 7 December. current concepts for. Smart health in orthopaedics. congress. 9th edition 6 & 7 December 2018 congress Trans-atlantic current concepts for Smart health in orthopaedics Congress Guide 2018 It is our pleasure to announce the 9 th IMUKA Congress The European Current

More information

Engaging UK Climate Service Providers a series of workshops in November 2014

Engaging UK Climate Service Providers a series of workshops in November 2014 Engaging UK Climate Service Providers a series of workshops in November 2014 Belfast, London, Edinburgh and Cardiff Four workshops were held during November 2014 to engage organisations (providers, purveyors

More information

Health Technology Assessment and the European Network for HTA

Health Technology Assessment and the European Network for HTA Health Technology Assessment and the European Network for HTA www.eunethta.eu Marcial Velasco Garrido, Technische Universität Berlin for the European Network for HTA, EUnetHTA Outline What is Health Technology

More information

New Approaches to Safety and Risk Management

New Approaches to Safety and Risk Management New Approaches to Safety and Risk Management 15 18 May 2011 The 3rd DIA China Annual Meeting, Bejjin, China Ayman Ayoub MD MSC (med) Safety Surveillance & Risk Management Pfizer Disclaimer The views/opinions

More information

HDR UK & Digital Innovation Hubs Introduction. 22 nd November 2018

HDR UK & Digital Innovation Hubs Introduction. 22 nd November 2018 HDR UK & Digital Innovation Hubs Introduction 22 nd November 2018 Health Data Research UK s vision To create a thriving, high-energy UK-wide network of inter-disciplinary research expertise that will:

More information

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS PRESS RELEASE FOR IMMEDIATE RELEASE PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP Plasminogen BLA

More information

Regulatory Science For Innovation

Regulatory Science For Innovation Regulatory Science For Innovation Fergal Donnelly European Commission Directorate-General for Research & Innovation Directorate 'Industrial Technologies' Unit 'Advanced Materials and Nanotechnology' The

More information

ehealth Ireland Ecosystem members of the ECHAlliance International Ecosystem Network European Ecosystem Network Update

ehealth Ireland Ecosystem members of the ECHAlliance International Ecosystem Network European Ecosystem Network Update ehealth Ireland Ecosystem members of the ECHAlliance International Ecosystem Network European Ecosystem Network Update Damian O Connor, Director Ecosystem Development, European Connected Health Alliance

More information

Research Brief. Clinicians and life sciences companies working together: What types of relationships do clinicians find most appealing?

Research Brief. Clinicians and life sciences companies working together: What types of relationships do clinicians find most appealing? Research Brief Clinicians and life sciences companies working together: What types of relationships do Truven Health Analytics was acquired by IBM in 2016 to help form a new business, Watson Health. Watson

More information

ETHICS & IMPACT EVALUATIONS

ETHICS & IMPACT EVALUATIONS ETHICS & IMPACT EVALUATIONS Nandini K. Kumar Former Deputy Director General, Senior Grade (ICMR) Dr. TMA Pai Endowment Chair & Adjunct Prof. Kasturba Medial College, Manipal University nandkku@gmail.com

More information

WP6 Genomics Organizing the societal debate on the use of genomic information in healthcare

WP6 Genomics Organizing the societal debate on the use of genomic information in healthcare WP6 Genomics Organizing the societal debate on the use of genomic information in healthcare Wannes Van Hoof, PhD & Chloé Mayeur, MA - Sciensano e-mail: wannes.vanhoof@sciensano.be chloe.mayeur@sciensano.be

More information

Adaptation of HTA reports: an effective way to use limited resources?

Adaptation of HTA reports: an effective way to use limited resources? Adaptation of HTA reports: an effective way to use limited resources? Iñaki Gutiérrez-Ibarluzea, Osteba, Basque Office for HTA. Ministry for Health, Basque Government Introducing the Basque Country Basque

More information

Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice

Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice 14 December 2017 10:30 CET Agenda How to use GoToWebinar Catherine

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium PROTECT Project Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium Content of Presentation About IAPO Overview of PROTECT Work Package 4 - New methods for data

More information

Health Innovations in Horizon 2020: the framework programme for research and innovation ( )

Health Innovations in Horizon 2020: the framework programme for research and innovation ( ) Health Innovations in Horizon 2020: the framework programme for research and innovation (2014-2020) Virginija Dambrauskaite, MD, PhD Scientific Officer, Medical Research Unit, Health Directorate Directorate-General

More information

Towards Code of Conduct on Processing of Personal Data for Purposes of Scientific Research in the Area of Health

Towards Code of Conduct on Processing of Personal Data for Purposes of Scientific Research in the Area of Health Towards Code of Conduct on Processing of Personal Data for Purposes of Scientific Research in the Area of Health 19/4/2017 BBMRI-ERIC WHAT HAPPENED SO FAR? 2 2015-2016 Holding a Day of Action on the draft

More information

UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015

UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015 UNITAID UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015 Page 2 UNITAID's role in the global response By connecting the

More information

Impact Case Study Template. Guidance Document

Impact Case Study Template. Guidance Document Guidance Document I. Introduction The College of Arts, Celtic Studies and Social Sciences (CACSSS) at UCC has an excellent record in fostering and sustaining high quality research at the forefront of international

More information

Research Development Request - Profile Template. European Commission

Research Development Request - Profile Template. European Commission Research Development Request - Profile Template European Commission Research Development Request Profile The following table can be used as a template for drafting a Research Development Request profile.

More information

Enhancing and focusing EU international cooperation in research and innovation: A strategic approach. Policy Research and Innovation

Enhancing and focusing EU international cooperation in research and innovation: A strategic approach. Policy Research and Innovation Enhancing and focusing EU international cooperation in research and innovation: A strategic approach A Rapidly Changing Context From a triad to a multipolar world STI increasingly internationally interconnected

More information

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer 13 December 2007 A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer Project Team Leela Barham Michelle Ng NERA Economic Consulting 15 Stratford Place London W1C 1BE United Kingdom Tel:

More information

Lundbeck s view on the EU IP systems

Lundbeck s view on the EU IP systems Lundbeck s view on the EU IP systems Forårsmøde IPR in the EU May 26 2011 H. Lundbeck A/S 1 Agenda The Innovative Pharmaceutical Industry and why IP is so important for Lundbeck Lundbeck s wish list for

More information

International Conference on Research Infrastructures 2014

International Conference on Research Infrastructures 2014 EUROPEAN COMMISSION [CHECK AGAINST DELIVERY] Máire GEOGHEGAN-QUINN European Commissioner responsible for Research, Innovation and Science International Conference on Research Infrastructures 2014 Conference

More information

Collaboration at time of market entry (from regulatory opinion to joint REA production)

Collaboration at time of market entry (from regulatory opinion to joint REA production) EMA-EUnetHTA Meeting Minutes 08 June 2017 11:00 to 16:00 CET Meeting Venue: ZIN Offices - Eekholt 4 1112 XH Diemen Role Chairs Present Regrets Name Wim Goettsch and Hans-Georg Eichler EUnetHTA: Chantal

More information

Societal engagement in Horizon 2020

Societal engagement in Horizon 2020 Societal engagement in Horizon 2020 19 June 2017 Brussels Colombe WARIN European Commission Research Executive Agency B5 - Spreading Excellence, Widening Participation, Science with and for Society Content

More information

CO-ORDINATION MECHANISMS FOR DIGITISATION POLICIES AND PROGRAMMES:

CO-ORDINATION MECHANISMS FOR DIGITISATION POLICIES AND PROGRAMMES: CO-ORDINATION MECHANISMS FOR DIGITISATION POLICIES AND PROGRAMMES: NATIONAL REPRESENTATIVES GROUP (NRG) SUMMARY REPORT AND CONCLUSIONS OF THE MEETING OF 10 DECEMBER 2002 The third meeting of the NRG was

More information